Nefopam


Concise Prescribing Info
Indications/Uses
Moderate acute and chronic pain.
Dosage/Direction for Use
Adult : PO Initial: 60 mg tid. Usual dose: 30-90 mg tid, adjusted according to patient’s response.
Dosage Details
Oral
Moderate acute and chronic pain
Adult: Initially, 60 mg tid. Usual dose: 30-90 mg tid, adjusted according to patient’s response.
Child: ≥12 yr Same as adult dose.
Elderly: Initially, 30 mg tid.
Administration
May be taken with or without food. May be taken w/ meals if GI discomfort occurs.
Contraindications
History of convulsive disorders. Concomitant use w/ MAOI(s).
Special Precautions
Patient w/ angle closure glaucoma, urinary retention, history of ischaemic heart disease. Hepatic and renal impairment. Elderly, childn. Pregnancy and lactation.
Adverse Reactions
Significant: Sympathomimetic effect (e.g. tachycardia, aggravation or precipitation of angina). Rarely, pink discolouration of urine.
Nervous: Insomnia, drowsiness, dizziness, paraesthesia, tremor, lightheadedness, nervousness, confusion, hallucinations, headache, syncope, euphoria, convulsions.
CV: Hypotension, palpitations, tachycardia.
GI: Nausea, vomiting, dry mouth, abdominal pain, diarrhoea.
Genitourinary: Urinary retention.
Ophthalmologic: Blurred vision.
Dermatologic: Sweating, angioedema.
Immunologic: Hypersensitivity reactions (e.g. erythema multiforme, anaphylaxis).
Patient Counseling Information
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Overdosage
Symptoms: Convulsions, hallucinations, agitation, coma, tachycardia w/ a hyperdynamic circulation. Management: Supportive treatment. May perform gastric lavage, forced emesis or diuresis. Administer activated charcoal, to prevent absorption. May give diazepam for convulsions, hallucinations, and β-adrenergic blockers for CV complications.
Drug Interactions
Increased risk of convulsion w/ TCA. Additive adverse effect w/ other antimuscarinic or sympathomimetic agents.
Potentially Fatal: May cause hypertensive crisis w/ MAOI(s).
Lab Interference
False positive result to screening test for benzodiazepines and opioids.
Action
Description: Nefopam is a potent, centrally-acting, non-opioid analgesic w/ rapid onset of action. It acts on the CNS, but the exact mechanism of action is still unclear. It also has antimuscarinic and sympathomimetic actions.
Pharmacokinetics:
Absorption: Absorbed from the GI tract. Time to peak plasma concentration: Approx 1-3 hr.
Distribution: Enters breast milk. Plasma protein binding: Approx 73%.
Metabolism: Extensively metabolised in the liver.
Excretion: Mainly via urine (<5% as unchanged drug); faeces (8%). Elimination half-life: Approx 4 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store below 25°C.
ATC Classification
N02BG06 - nefopam ; Belongs to the class of other analgesics and antipyretics.
Disclaimer: This information is independently developed by MIMS based on Nefopam from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in